Oleuropein prevents doxorubicin-induced cardiomyopathy interfering with signaling molecules and cardiomyocyte metabolism

Journal of Molecular and Cellular Cardiology

Volumn 69, Issue , 2014, Pages 4-16

  Andreadou, Ioanna ^a   Mikros, Emmanuel ^a   Ioannidis, Konstantinos ^a   Sigala, Fragiska ^b   Naka, Katerina ^c   Kostidis, Sarantos ^a   Farmakis, Dimitrios ^b   Tenta, Roxane ^d   Kavantzas, Nikolaos ^b   Bibli, Sofia Iris ^a   Gikas, Evangelos ^a   Skaltsounis, Leandros ^a   Kremastinos, Dimitrios Th ^b   Iliodromitis, Efstathios K ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF IOANNINA   (Greece)

^d HAROKOPIO UNIVERSITY   (Greece)

Author keywords

Cardiomyopathy; Doxorubicin; Metabonomics; Oleuropein; Signaling molecules

Indexed keywords

BIG ENDOTHELIN 1; CARBONYL DERIVATIVE; DOXORUBICIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; MALONALDEHYDE; OLEUROPEIN; PROTEIN KINASE B; ANTINEOPLASTIC ANTIBIOTIC; IRIDOID; VASODILATOR AGENT;

ADULT; ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BIOMICS; CARDIOMYOPATHY; CELL METABOLISM; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ENERGY METABOLISM; ENZYME ACTIVATION; HEART LEFT VENTRICLE CONTRACTILITY; HEART MUSCLE CELL; HEART PROTECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MALE; METABOLITE; METABONOMICS; MORTALITY; MTT ASSAY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT; TRANSTHORACIC ECHOCARDIOGRAPHY; ANIMAL; CARDIOMYOPATHIES; CHEMICALLY INDUCED; CYTOLOGY; DRUG EFFECTS; ECHOCARDIOGRAPHY; ENZYME IMMUNOASSAY; METABOLISM; METABOLOMICS; PATHOLOGY; TOXICITY; WESTERN BLOTTING; WISTAR RAT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLOTTING, WESTERN; CARDIOMYOPATHIES; CELL PROLIFERATION; DOXORUBICIN; ECHOCARDIOGRAPHY; ENERGY METABOLISM; IMMUNOENZYME TECHNIQUES; INTERLEUKIN-6; IRIDOIDS; MALE; METABOLOMICS; MYOCYTES, CARDIAC; OXIDATIVE STRESS; RATS; RATS, WISTAR; VASODILATOR AGENTS;

EID: 84895458646     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2014.01.007     Document Type: Article

References (68)

1. Felker G.M., Thompson R.H., Hare J.M., Hruban R.H., Chemetson D.E., Howard D.L., et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000, 342:1077-1084.
2. Gratia S., Kay L., Potenza L., Seffouth A., Novel-Chate V., Schnebelen C., et al. Inhibition of AMPK signaling by doxorubicin: at the crossroads of the cardiac responses to energetic, oxidative and genotoxic effects. Cardiovasc Res 2012, 95:290-295.
3. Simunek T., Sterba M., Popelova O., Adamcova M., Hirdina R., Gersi V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 2009, 61:154-171.
4. Solem L.E., Henry T.R., Wallace K.B. Disruption of mitochondrial calcium homeostasis following chronic doxorubicin administration. Toxicol Appl Pharmacol 1994, 129:214-222.
5. Tokarska-Schlattner M., Zaug M., Zuppinger C., Wallimann T., Schlattner U. New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetic. J Mol Cell Cardiol 2006, 41:389-405.
6. Wang G.W., Klein J.B., Kang Y.I. Metallothionein inhibits doxorubicin-induced mitochondrial cytochrome c release and caspase-3 activation in cardiomyocytes. J Pharmacol Exp Ther 2001, 298:461-468.
7. Lebrecht D., Geist A., Ketelsen U.-P., Haberstroh J., Setzer B., Walker U.A. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. Br J Pharmacol 2007, 151:771-778.
8. Zhang S., Liu X., Bawa-Khalfe T., Lu L.S., Lyu Y.L., Liu L.F., et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012, 18:1639-1642.
9. Andreadou I., Iliodromitis E.K., Mikros E., Constantinou M., Agalias A., Magiatis P., et al. The olive constituent oleuropein exhibits anti-ischemic, anti-oxidative and hypolipidemic effects in anesthetized rabbits. J Nutr 2006, 136:2213-2219.
10. Andreadou I., Sigala F., Iliodromitis E.K., Papaefthimiou M., Sigalas C., Aligiannis N., et al. Acute doxorubicin cardiotoxicity is successfully treated with the phytochemical oleuropein through suppression of oxidative and nitrosative stress. J Mol Cell Cardiol 2007, 42:549-558.
11. McTiernan C. Fighting doxorubicin-induced cardiotoxicity with adiponectin. Cardiovasc Res 2011, 89:262-266.
12. Octavia Y., Tocchetti C.G., Gabrielson K.L., Janssens S., Crijns H.J., Moens A.L. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 2012, 52:1213-1225.
13. Zoidou E., Melliou E., Gikas E., Tsarbopoulos A., Magiatis P., Skaltsounis A.L. Identification of Throuba Thassos, a traditional Greek table olive variety, as a nutritional rich source of oleuropein. J Agric Food Chem 2010, 58:46-50.
14. Odiatou E.M., Skaltsounis A.L., Constantinou A.I. Identification of the factors responsible for the in vitro pro-oxidant and cytotoxic activities of the olive polyphenols oleuropein and hydroxytyrosol. Cancer Lett 2013, 330:113-121.
15. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63.
16. Vistica D.T., Skehan P., Scudiero D., Monks A., Pittman A., Boyd M.R. Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production. Cancer Res 1991, 51:2515-2520.
17. Abdel-Aleem S., El-Merzabani M.M., Sayed-Ahmed M., Taylor D.A., Lowe J.E. Acute and chronic effects of adriamycin on fatty acid oxidation in isolated cardiac myocytes. J Mol Cell Cardiol 1997, 29:789-797.
18. Boccio P., DiDeo A., De Curtis A., Celli N., Iacoviello L., Rotilio D. Liquid chromatography-tandem mass spectrometry analysis of oleuropein and its metabolite hydroxytyrosol in rat plasma and urine after oral administration. J Chromatogr B 2003, 785:47-56.
19. Tan H.W., Tuck K.L., Stupans I., Hayball P.J. Simultaneous determination of oleuropein and hydroxytyrosol in rat plasma using liquid chromatography with fluorescence detection. J Chromatogr B 2003, 785:187-191.
20. Kapelanski D.P., Daly J.M., Copeland E.M., Dudrick S.J. Doxorubicin pharmacokinetics - the effects of protein deprivation. J Surg Res 1981, 30:331-337.
21. Schiller N.B., Shah P.M., Crawford M., DeMaria A., Devereux R., Feigenbaum H., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography committee on standards, subcommittee on quantitation of two-dimensional echocardiograms. J Am Soc Echocardiogr 1989, 2:358-367.
22. Arnold R.D., Slack J.E., Straubinger R.M. Quantification of doxorubicin and metabolites in rat plasma and small volume tissue samples by liquid chromatography/electrospray tandem mass spectroscopy. J Chromatogr B 2004, 808:141-152.
23. Yagmurca M., Fadillioglu E., Erdogan H., Ucar M., Sogut S., Irmak M.K. Erdosteine prevents doxorubicin-induced cardiotoxicity in rats. Pharmacol Res 2003, 48:377-382.
24. Papalambros E., Sigala F., Georgopoulos S., Panou N., Kavantzas N., Agapitos M., et al. Vascular endothelial growth factor and matrix metalloproteinase-9 expression in human carotid atherosclerotic plaques: relationship with plaque destabilization via neovascularization. Cerebrovasc Dis 2004, 18:160-165.
25. Andreadou I., Farmakis D., Prokovas E., Sigala F., Zoga A., Spyridaki K., et al. Short-term statin administration in hypercholesterolemic rabbits resistant to postconditioning: effects on infarct size, endothelial nitric oxide synthase and nitro-oxidative stress. Cardiovasc Res 2012, 94:501-509.
26. Andreadou I., Papaefthimiou M., Zira A., Constantinou M., Sigala F., Skaltsounis A.L., et al. Metabonomic identification of novel biomarkers in doxorubicin cardiotoxicity and protective effect of the natural antioxidant oleuropein. NMR Biomed 2009, 22:585-592.
27. 1H NMR-based metabonomic investigation of the effect of two different exercise sessions on the metabolic fingerprint of human urine. J Proteome Res 2010, 9:6405-6416.
28. Xia J., Wishart D.S. Web-based inference of biological patterns, functions and pathways from metabolomic data using MetaboAnalyst. Nat Protoc 2011, 6:743-760.
29. Hydock D.S., Lien C.Y., Jensen B.T., Schneider C.M., Hayward R. Exercise preconditioning provides long-term protection against early chronic doxorubicin cardiotoxicity. Integr Cancer Ther 2011, 10:47-57.
30. Ohkura K., Lee J.-D., Shimizu H., Nakano A., Uzui H., Horikoshi M., et al. Mitochondrials complex I activity is reduced in latent adriamycin-induced cardiomyopathy of rat. Mol Cell Biochem 2003, 248:203-208.
31. Li K., Sung R.Y.T., Huang W.Z., Yang M., Pong N.H., Lee S.M., et al. Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin. Circulation 2006, 113:2211-2220.
32. Schwarz E.R., Pollick C., Dow J., Patterson M., Birnbaum Y., Kloner R.A. A small animal model of non-ischemic cardiomyopathy and its evaluation by transthoracic echocardiography. Cardiovasc Res 1998, 39:216-223.
33. Koh E., Nakamura T., Takahashi H. Troponin-T and brain natriuretic peptide as predictors for adriamycin-induced cardiomyopathy in rats. Circ J 2004, 68:163-167.
34. Koneru S., Penumathsa S.V., Thirunavukkarasu M., Zhan L., Maulik N. Thioredoxin-1 gene delivery induces heme oxygenase-1 mediated myocardial preservation after chronic infarction in hypertensive rats. Am J Hypertens 2009, 22:183-190.
35. Taniyama Y., Walsh K. Elevated myocardial Akt signaling ameliorates doxorubicin-induced congestive heart failure and promotes heart growth. J Mol Cell Cardiol 2002, 34:1241-1247.
36. Lopez-Andres N., Rousseau A., Akhtar R., Calvier L., Inigo C., Labat C., et al. Cardiotrophin 1 is involved in cardiac, vascular, and renal fibrosis and dysfunction. Hypertension 2012, 60:563-573.
37. Migrino R.Q., Aggarwal D., Konorev E., Brahmbhatt T., Bright M., Kalyanaraman B. Early detection of doxorubicin cardiomyopathy using two-dimensional strain echocardiography. Ultrasound Med Biol 2008, 34:208-214.
38. Lovric-Bencic M., Sikiric P., Hanzevacki J.S., Seiwerth S., Rogic D., Kusec V., et al. Doxorubicin-congestive heart failure-increased big endothelin-1 plasma concentration: reversal by amlodipine, losartan and gastric pentadecapeptide BPC157 in rat and mouse. J Pharmacol Sci 2004, 95:19-26.
39. Weinstein D.M., Mihm M.J., Bauer J.A. Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice. J Pharmacol Exp Ther 2000, 294:396-401.
40. Pacher P., Liaudet L., Bai P., Mabley J.G., Kaminski P.M., Virag L., et al. Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation 2003, 107:896-904.
41. Aldieri E., Bergandi L., Riganti C., Costamagna C., Bosia A., Chigo D. Doxorubicin induces an increase of nitric oxide synthesis in rat cardiac cells that is inhibited by iron supplementation. Toxicol Appl Pharmacol 2002, 185:85-90.
42. Cole M.P., Chaiswing L., Oberley T.D., Edelmann S.E., Piascik M.T., Lin S.M., et al. The protective roles of nitric oxide and superoxide dismutase in adriamycin-induced cardiotoxicity. Cardiovasc Res 2006, 69:186-197.
43. Neilan T.G., Blake S.L., Ichinose F., Raher M.J., Buys E.S., Jassal D.S., et al. Disruption of nitric oxide synthase 3 protects against the cardiac injury, dysfunction, and mortality induced by doxorubicin. Circulation 2007, 116:506-514.
44. Deng S., Kruger A., Schmidt A., Metzger A., Yan T., Godtel-Armbrust U., et al. Differential roles of nitric oxide synthase isozymes in cardiotoxicity and mortality following chronic doxorubicin treatment in mice. Naunyn Schmiedebergs Arch Pharmacol 2009, 380:25-34.
45. Kobayashi N., Nishikimi T., Horinaka S., Ishimitsu T., Matsuoka H. Effects of TCV-116 on expression of NOS and adrenomedullin in failing heart of Dahl salt sensitive rats. Atherosclerosis 2001, 156:255-265.
46. Dimmeler S., Fleming I., Fisslthaler B., Hermann C., Busse R., Zeilher A.M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999, 399:601-605.
47. Negoro S., Oh H., Tone E., Kunisada K., Fujio Y., Walsh K. Glycoprotein 130 regulates cardiac myocyte survival in doxorubicin-induced apoptosis through phosphatidylinositol 3-kinase/Akt phosphorylation and Bcl-xl caspase-3 interaction. Circulation 2001, 103:555-561.
48. Hardie D.G. AMP activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev 2011, 25:1895-1908.
49. Konichi M., Haraguchi G., Ohigashi H., Ishihara T., Saito K., Nakano Y., et al. Adiponectin protects against doxorubicin-induced cardiomyopathy by anti-apoptotic effects through AMPK up-regulation. Cardiovasc Res 2011, 89:309-319.
50. Chen Z.P., Mitchelhill K.J., Michell B.J., Stapleton D., Rodriguez-Crespo I., Witters L.A., et al. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett 1999, 443:285-289.
51. Sasaki H., Asanuma H., Fujita M., Takahama H., Wakeno M., Ito S., et al. Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. Circulation 2009, 119:2568-2577.
52. Menendez J.A., Joven J., Aragons G., Barrajon-Catalan E., Beltran-Debon R., Borras Linares I., et al. Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil. A new family of gerosuppressant agents. Cell Cycle 2013, 12:555-578.
53. Hulshman M., Stanek B., Frey B., Sturm B., Putz D., Kos T., et al. Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. J Am Coll Cardiol 1998, 32:1695-1700.
54. Bien S., Riad A., Ritter C.A., Gratz M., Olshausen F., Westermann D., et al. The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy. Cancer Res 2007, 67:10428-10435.
55. Wagner F.D., Buz S., Knosalla C., Hetzer R., Hocher B. Modulation of circulating endothelin-1 and big endothelin by nitric oxide inhalation following left ventricular assist device implantation. Circulation 2003, 108:278-284.
56. Lou H., Danelisen I., Singal P.K. Cytokines are not upregulated in adriamycin-induced cardiomyopathy and heart failure. J Mol Cell Cardiol 2004, 36:683-690.
57. Hare J., Loh E., Creager M., Colucci W.S. Nitric oxide inhibits the positive inotropic response to b-adrenergic stimulation in humans with left ventricular dysfunction. Circulation 1995, 92:2198-2203.
58. Yoshizumi M., Perella M., Burnett J., Lee M.E. Tumor necrosis factor down-regulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 1993, 73:205-209.
59. Bordoni A., Biagi P., Hrelia S. The impairment of essential fatty acid metabolism as a key factor in doxorubicin-induced damage in cultured rat cardiomyocytes. Biochim Biophys Acta 1999, 1440:100-106.
60. Tan G., Lou Z., Liao W., Zhu Z., Dong X., Zhang W., et al. Potential biomarkers in mouse myocardium of doxorubicin-induced cardiomyopathy: a metabonomic method and its application. PLoS One 2011, 6:e27683.
61. Wakasugi S., Fischman A.J., Babich J.W., Callahan R.J., Elmaleh D.R., Wilkinson R., et al. Myocardial substrate utilization and left ventricular function in adriamycin cardiomyopathy. J Nucl Med 1993, 34:1529-1535.
62. Stanley W.C. Changes in cardiac metabolism: a critical step from stable angina to ischaemic cardiomyopathy. Eur Heart J Suppl 2001, 3:O2-O7.
63. Drake K.J., Sidorov V.Y., McGuinness O.P., Wasserman D.H., Wikswo J.P. Amino acids as metabolic substrates during cardiac ischemia. Exp Biol Med 2012, 237:1369-1378.
64. Taegtmeyer H., Harinstein M.E., Gheorghiade M. More than bricks and mortar: comments on protein and amino acid metabolism in the heart. Am J Cardiol 2008, 101:3E-7E.
65. Razeghi P., Sharma S., Ying J., Li Y.P., Stepkowski S., Reid M.B., et al. Atrophic remodeling of the heart in vivo simultaneously activates pathways of protein synthesis and degradation. Circulation 2003, 108:2536-2541.
66. Baskin K.K., Taegtmeryer H. An expanded role for AMP-activated protein kinase: regulator of myocardial protein degradation. ICM 2011, 21:124-127.
67. Bijland S., Mancini S.J., Salt I.P. Role of AMP-activated protein kinase in adipose tissue metabolism and inflammation. Clin Sci (Lond) 2013, 124:491-507.
68. Herman E.H., Zhang J., Lipshultz S.E., Rifai N., Chadwick D., Takeda K., et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 1999, 17:2237-2243.